News Center

News Center

News Center

First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418

2025-06-05

Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting
2025-05-22

FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
2025-04-30

DualityBio 2024 Environmental. Social and Governanee Report
2025-04-29

DualityBio Presented Early Clinical and Preclinical Data for Novel ADC Therapy Candidates at AACR 2025
2025-04-24

ASCO 2025: DualityBio to present data from ADC pipeline in oral presentations at 2025 ASCO Annual Meeting
2025-04-15

DualityBio (9606.HK) Officially Lists on Hong Kong Stock Exchange, Embarking on a New Chapter

«
1
2
3
»

Scan the code to follow DualityBio official wechat

Phone：021-2601 8730

Address：Full floor, 11th floor, tower a, Datang International Plaza,China

Construction Engineering Group, No. 868 Yinghua Road, Pudong New Area, Shanghai